308 



Index 



Radium. See Radiation 

 Raileanu, D., 269 



Rappaport, H., 205, 232, 243, 248. 260 

 Rat. adrenalectomy affecting lymphatic organs, 

 112 

 compound vacuoles in spleen, 59 

 esterase activity in lymphatic tissue. 44 

 hematopoiesis in, 23 



hydrolytic enzymes in normal lvmphoid ele- 

 ments, 196 

 intestinal lymphatics of, lymphocyte turn- 

 over in, 68 

 lymphocytic malignancies in. 104 

 radiation of, abortive rise in lymphocytes 

 after, 136 

 lymphocyte decrease after, 132 

 lymphoid tissue after, 131 

 recovery after, 139 



survival time of lymphocytes in, 129 

 thoracic duel cells after, 130 

 sulfhydryl groups in, 38 

 thoracic duct drainage of, (is 

 transfused cells in, survival time of, 69 

 Reaction. Hurstone, histidine after, 37 

 Feulgen nucleal, 34 

 Millon. tyrosine after, 37 

 nadi, for cytochrome oxidase, 46 

 PAS, and glycogen content, 38 

 Rehuck, J. W.. 71-80, 260-286 

 Recovery stage, after radiation. 139-140 

 Rectal lymphoma, 230 



Reed-Sternberg tells, enzyme at thin in. 197, 

 198 

 in Hodgkins disease. 232. 236, 239. 267 

 desmoplastic lymphoma, 188 

 granuloma, 191 

 sarcoma, 246 

 Refractile granules, radiation affecting, 138 

 Regeneration, after radiation, 136. 139 

 Reinfusion of withdrawn lymphocytes, 68 

 Repopulation, of lymphatic tissue, adreno- 

 cortical hormones affecting, 119 

 ol lymphocytes, after radiation, 139 

 Resistant e, to grafts. 100 



of lymphocytes to x-rays, 128 

 Respiratory infections, viral, lymphocytosis in, 



149 ' 

 Reticulocues, in lymphatic leukemia, chronic, 



214 

 Reticulocytosis, in lymphosarcoma, 231 

 Reticuloendothelial cells, 262 

 adrenocortical hormones affecting, 120 

 in canine malignant lymphoma, 166 

 in cell transfer studies, 85, 93 

 in leukemia. 181 



lymphocytokaryorrhe< (it hormones a Meeting, 

 119 



Reticuloendotheliosis, leukemic, 267, 272 

 lvmphocytic, 276 

 monocytic, 273 

 reticular cells in, 3, 5, 9 

 Reticulum cells, 262, 263-264 

 in antibody formation, 283 

 blood-forming, 270-272 



leukemic, 272-275 

 endoplasmic, electron microscopx of, 57 



in monocytic leukemia, 62 

 and erythrocytes, 12 

 in Ewing's tumor of hone, 269 

 in follicular lymphoma, 188. 204 

 in Hodgkin's disease, 232, 267 

 granuloma, 239 

 sarcoma, 239, 246 

 lacking cytoplasm, 17 

 in Letterer-Sivve disease, 269 

 leukemia, 272 



leukemic manifestation of malignancy, 266 

 in leukemic reticuloendotheliosis, 3, 5, 9 

 lymphoblast, 275 

 lymphocytes, 13, 14, 15 

 Cortisol affecting, 118 

 from hematopoietic reticular cells, 16 

 in hyperplastic lymph node, 15 

 mitosis in, 17 

 lymphoma, with follicular and hmphoevtic 

 lymphoma, 188 

 transitions in, 184 

 mirror-image, 268 

 and normoblasts, 12. 18 

 phagocytic, 5, 120 



in thymus. 16 

 and plasma cells, 14. 15. 18. 284-285 

 pleomorphic, 269 

 radiation affecting, 131, 138 



mitosis alter, 139 

 sarcoma, 246, 266-269 



follicular lymphoma with, after lymph- 



angiosarcoma, 190 

 transitions in, 182 

 storage, 264-206 



stroma cells, phagocytizing nuclear and cyto- 

 plasmic particles, 120 

 tumors arising from, 158, 159 

 Reutilization of nuclear ami cytoplasmic ma- 

 terial, adrenocortical hormones affecting. 

 120 

 Rheumatoid arthritis, plasmacytosis in, 285 

 Rihonuclease, effect on basophilia, 35 

 Rich's splenic tumor cells, in cell transfer 

 studies, 87 

 radiation affecting, 138 

 Richter. M. \., 158-161, 260 

 Riquire, G., 102 

 RNA, in cytoplasm, and staining reaction, 37 



nonmetabolized, reutilization of. 120 

 Roherts, J. C„ 82-95, 103, 283 



